In a part-draft, part-final guidance issued on Tuesday, the US Food and Drug Administration (FDA) finalized its policy on the quantity of reserve samples to be retained for bioequivalence (BE) and ...
Reflecting changes in testing technology, a new and immediately effective guidance from the US Food and Drug Administration (FDA) updates the agency’s approach to retention of reserve samples for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results